99mtc-pyp
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2017 (NCT03414632)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 99-technetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05951816 | Phase 1 | Jul 31, 2023 | Attralus, Inc., University of Tennessee |
| NCT04899180 | Early Phase 1 (Phase 1) | Dec 31, 2021 | Mayo Clinic |
| NCT03414632 | Early Phase 1 (Phase 1) | Dec 1, 2017 | Mayo Clinic, Pfizer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Attralus, Inc. | For profit | 1 | 0 | 1 | 2023 |
| Pfizer | For profit | 1 | 0 | 1 | 2017 |
| University of Tennessee | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1